Innovative Medicines Initiative (IMI) (https://www.imi.europa.eu) is a partnership between the European Union and the European pharmaceutical industry, working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. They do this by facilitating collaboration between the key players involved in healthcare research. IMI has now launched its final Call for proposals under IMI2. Deadline for proposals: 29 September 2020.
- IMI2 – Call22
Read more at www.imi.europa.eu/apply-funding/open-calls/imi2-call-22
- IMI2 – Call23
Read more at www.imi.europa.eu/apply-funding/open-calls/imi2-call-23
Open calls for clinical investigators interested in joining the EU-wide COVID19 Clinical Trial network
The purpose of the network is to promote and enable a coordinated approach for planning and implementation of COVID19 clinical trials in Europe. This, to avoid fragmentation and ensure that new trials that will start are sufficiently powerful and will produce robust results to provide policy guidance and allow for regulatory decisions.
Two existing large trials, DisCoVeRy and REMAP-COVID have received additional funds from EU to further expand and include more clinical research sites.
For more information and participation, please have a look at the websites: